<1>
[Use Link to view the full text]
Unique Identifier 97454195
Authors Szabo BM. van Veldhuisen DJ. de Graeff PA. Lie KI.
Institution Department of Cardiology/Thoraxcenter, University Hospital Groningen, The Netherlands.
Title: Alterations in the prognosis of chronic heart failure: an overview of the major mortality trials.
Source: Cardiovascular Drugs & Therapy. 11(3):427-34, 1997 Jul.
Abstract: Treatment of chronic heart failure (CHF) remains a major medical problem. Although in the last decades the benefits of several therapies in different patient populations with left ventricular dysfunction have been established, morbidity and mortality of CHF patients are high. Consequently, in the last decade improvement of survival has become the primary therapeutic endpoint in CHF studies, and the evaluation of the influence of (new) drugs on mortality has become crucial. In the present article an overview of the large mortality trials is given, and the shifts and alterations in the drug treatment strategy of CHF are discussed.

<2>
[Use LINK to view the full text]
Unique Identifier 97430034
Authors Philbin EF. Cotto M. Rocco TA Jr. Jenkins PL.
Institution Cardiac Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Title: Association between diuretic use, clinical response, and death in acute heart failure.
Source: American Journal of Cardiology. 80(4):519-22, 1997 Aug 15.
Abstract: Because the impact of diuretic use on mortality in acute congestive heart failure (CHF) is not known, we examined the association between drug use, fluid balance, and death among 1,150 patients hospitalized for evaluation and treatment of CHF. After adjusting for other relevant intergroup differences, we observed that less net weight loss and a greater number of intravenous drug doses retained significant predictive value for death, suggesting that more frequent diuretic dosing or diuretic resistance may be related to mortality in acute CHF.

<3>
[Use Link to view the full text]
Unique Identifier 97195474
Authors Psaty BM. Smith NL. Siscovick DS. Koepsell TD. Weiss NS. Heckbert SR. Lemaitre RN. Wagner EH. Furberg CD.
Institution Cardiovascular Health Research Unit, Seattle, WA 98101, USA.
Title: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
Source: JAMA. 277(9):739-45, 1997 Mar 5. [see comments]
Abstract: OBJECTIVE: To review the scientific evidence concerning the safety and efficacy of various antihypertensive therapies used as first-line agents and evaluated in terms of major disease end points. DATA SOURCES: MEDLINE searches and previous meta-analyses for 1980 to 1995. DATA SELECTION: We selected long-term studies that assessed major disease end points as an outcome. For the meta-analysis, we chose placebo-controlled randomized trials. For randomized trials using surrogate end points such as blood pressure, we selected the largest studies that evaluated multiple drugs. Where clinical trial evidence was lacking, we relied on information from observational studies. DATA SYNTHESIS: Diuretics and beta-blockers have been evaluated in 18 long-term randomized trials. Compared with placebo, beta-blocker therapy was effective in preventing stroke (relative risk [RR], 0.71; 95% confidence interval [CI], 0.59-0.86) and congestive heart failure (RR, 0.58; 95% CI, 0.40-0.84). The findings were similar for high-dose diuretic therapy (for stroke, RR, 0.49; 95% CI, 0.39-0.62; and for congestive heart failure, RR, 0.17; 95% CI, 0.07-0.41). Low-dose diuretic therapy prevented not only stroke (RR, 0.66; 95% CI, 0.55-0.78) and congestive heart failure (RR, 0.58; 95% CI, 0.44-0.76) but also coronary disease (RR, 0.72; 95% CI, 0.61-0.85) and total mortality (RR, 0.90; 95% CI, 0.81-0.99). Although calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure in hypertensive patients, the clinical trial evidence in terms of health outcomes is meager. For several short-acting dihydropyridine calcium channel blockers, the available evidence suggests the possibility of harm. Whether the long-acting formulations and the nondihydropyridine calcium channel blockers are safe and prevent major cardiovascular events in patients with hypertension remains untested and therefore unknown. CONCLUSION: Until the results of large long-term clinical trials evaluating the effects of calcium channel blockers and ACE inhibitors on cardiovascular disease incidence are completed, the available scientific evidence provides strong support for the current national guidelines, which recommend diuretics and beta-blockers as firstline agents and low-dose therapy for all antihypertensive agents.

[litsrch98/footer_generic.html]